Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient

被引：4

作者：

Freedman, Rachel A. ^{[1
]}

Muss, Hyman B. ^{[2
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27514 USA

来源：

JOURNAL OF GERIATRIC ONCOLOGY | 2014年 / 5卷 / 01期

关键词：

Older-women; Breast cancer; Metastatic; Human Epidermal Growth Factor; Receptor; 2; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; CLINICAL-OUTCOMES; ELDERLY-PATIENTS; FOLLOW-UP; 1ST-LINE CHEMOTHERAPY; PLUS TRASTUZUMAB; WEEKLY DOCETAXEL; HEART-FAILURE; SINGLE-AGENT;

D O I：

10.1016/j.jgo.2013.10.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treating older patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer is often challenging. This is largely due to the issues providers face in making decisions in the setting of limited efficacy and toxicity data specific to older women in addition to the competing challenges of managing comorbidity and preserving functional status. Here, we discuss currently available treatment regimens and other important issues to consider when treating older patients with metastatic, HER2-positive disease. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：2 / 7

页数：6

共 58 条

[1] Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women [J].

Bajetta, E ;

Procopio, G ;

Celio, L ;

Gattinoni, L ;

Della Torre, S ;

Mariani, L ;

Catena, L ;

Ricotta, R ;

Longarini, R ;

Zilembo, N ;

Buzzoni, R .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2155-2161

[2]

Balducci L, 2000, ONCOLOGY-NY, V14, P221

[3]

Baselga J, 2001, ONCOLOGIST, V6, P26

[4] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[5] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[6] Undertreatment strongly decreases prognosis of breast cancer in elderly women [J].

Bouchardy, C ;

Rapiti, E ;

Fioretta, G ;

Laissue, P ;

Neyroud-Caspar, I ;

Schäfer, P ;

Kurtz, J ;

Sappino, AP ;

Vlastos, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3580-3587

[7] Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study [J].

Bowles, Erin J. Aiello ;

Wellman, Robert ;

Feigelson, Heather Spencer ;

Onitilo, Adedayo A. ;

Freedman, Andrew N. ;

Delate, Thomas ;

Allen, Larry A. ;

Nekhlyudov, Larissa ;

Goddard, Katrina A. B. ;

Davis, Robert L. ;

Habel, Laurel A. ;

Yood, Marianne Ulcickas ;

McCarty, Catherine ;

Magid, David J. ;

Wagner, Edward H. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17) :1293-1305

[8] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm [J].

Burstein, HJ ;

Harris, LN ;

Marcom, PK ;

Lambert-Falls, R ;

Havlin, K ;

Overmoyer, B ;

Friedlander, RJ ;

Gargiulo, J ;

Strenger, R ;

Vogel, CL ;

Ryan, PD ;

Ellis, MJ ;

Nunes, RA ;

Bunnell, CA ;

Campos, SM ;

Hallor, M ;

Gelman, R ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2889-2895

[9] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer [J].

Burstein, HJ ;

Kuter, I ;

Campos, SM ;

Gelman, RS ;

Tribou, L ;

Parker, LM ;

Manola, J ;

Younger, J ;

Matulonis, U ;

Bunnell, CA ;

Partridge, AH ;

Richardson, PG ;

Clarke, K ;

Shulman, LN ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2722-2730

[10] Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J].

Cardinale, Daniela ;

Colombo, Alessandro ;

Sandri, Maria T. ;

Lamantia, Giuseppina ;

Colombo, Nicola ;

Civelli, Maurizio ;

Martinelli, Giovanni ;

Veglia, Fabrizio ;

Fiorentini, Cesare ;

Cipolla, Carlo M. .

CIRCULATION, 2006, 114 (23) :2474-2481

← 1 2 3 4 5 6 →